Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis

Arthritis and Rheumatology

Volumn 70, Issue 5, 2018, Pages 679-689

  Burmester, Gerd R ^a   McInnes, Iain B ^b   Kremer, Joel M ^c   Miranda, Pedro ^d   Vencovský, Jiří ^e   Godwood, Alex ^f,i   Albulescu, Marius ^f,j   Michaels, M Alex ^g   Guo, Xiang ^g   Close, David ^f,j   Weinblatt, Michael ^h  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c ALBANY MEDICAL COLLEGE   (United States)

^d Centro de Estudios Reumatologicos   (Chile)

^e INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^f MEDIMMUNE LTD   (United Kingdom)

^g MEDIMMUNE   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ Heptares Therapeutics Ltd   (United Kingdom)

^j ASTRAZENECA   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; C REACTIVE PROTEIN; CHLOROQUINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; GOLIMUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR ALPHA; HYDROXYCHLOROQUINE; LEFLUNOMIDE; MACROPHAGE DERIVED CHEMOKINE; MAVRILIMUMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVERSE DRUG REACTION; ALLERGIC REACTION; ANEMIA; ARTICLE; BACKACHE; BRONCHITIS; CHOLELITHIASIS; CLINICAL ASSESSMENT; DAS28; DIARRHEA; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GASTROENTERITIS; HEADACHE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INFECTION; INFLUENZA; LONG TERM CARE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MIDDLE AGED; MULTICENTER STUDY; NEUTROPENIA; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERUS MYOMA; CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; TREATMENT OUTCOME;

EID: 85044627852     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40420     Document Type: Article

References (45)

1. Van Onna M, Boonen A. The challenging interplay between rheumatoid arthritis, ageing and comorbidities. BMC Musculoskelet Disord 2016;17:184.
2. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013;52:53–61.
3. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 2015;386:258–65.
4. Berghen N, Teuwen LA, Westhovens R, Verschueren P. Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study. Clin Rheumatol 2015;34:1687–95.
5. Cornish AL, Campbell IK, McKenzie BS, Chatfield S, Wicks IP. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009;5:554–9.
6. Avci AB, Feist E, Burmester GR. Targeting GM-CSF in rheumatoid arthritis. Clin Exp Rheumatol 2016;34 Suppl 98:39–44.
7. Greven DE, Cohen ES, Gerlag DM, Campbell J, Woods J, Davis N, et al. Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis. Ann Rheum Dis 2015;74:1924–30.
8. Cook AD, Louis C, Robinson MJ, Saleh R, Sleeman MA, Hamilton JA. Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation. Arthritis Res Ther 2016;18:287.
9. Fleetwood AJ, Cook AD, Hamilton JA. Functions of granulocyte-macrophage colony-stimulating factor. Crit Rev Immunol 2005;25:405–28.
10. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008;8:533–44.
11. Zhan Y, Cheers C. Haemopoiesis in mice genetically lacking granulocyte-macrophage colony stimulating factor during chronic infection with Mycobacterium avium. Immunol Cell Biol 2000;78:118–23.
12. Calisto Perez C, Leon R, Leon F, Ng SL. Rheumatoid arthritis and anemia: the impact of different anti-inflammatory therapies on hemoglobin levels: an observational study. Bol Asoc Med P R 2012;104:34–41.
13. Lazaro E, Morel J. Management of neutropenia in patients with rheumatoid arthritis. Joint Bone Spine 2015;82:235–9.
14. Crotti C, Raimondo MG, Becciolini A, Biggioggero M, Favalli EG. Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Des Devel Ther 2017;11:211–23.
15. Chen BD, Mueller M, Chou TH. Role of granulocyte/macrophage colony-stimulating factor in the regulation of murine alveolar macrophage proliferation and differentiation. J Immunol 1988;141:139–44.
16. Akagawa KS, Kamoshita K, Tokunaga T. Effects of granulocyte-macrophage colony-stimulating factor and colony-stimulating factor-1 on the proliferation and differentiation of murine alveolar macrophages. J Immunol 1988;141:3383–90.
17. Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, Trapnell BC. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 2001;15:557–67.
18. Yoshida M, Korfhagen TR, Whitsett JA. Surfactant protein D regulates NF-κ B and matrix metalloproteinase production in alveolar macrophages via oxidant-sensitive pathways. J Immunol 2001;166:7514–9.
19. Borie R, Danel C, Debray MP, Taille C, Dombret MC, Aubier M, et al. Pulmonary alveolar proteinosis. Eur Respir Rev 2011;20:98–107.
20. Minter RR, Cohen ES, Wang B, Liang M, Vainshtein I, Rees G, et al. Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis. Br J Pharmacol 2013;168:200–11.
21. Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 2013;72:1445–52.
22. Burmester GR, McInnes IB, Kremer J, Miranda P, Korkosz M, Vencovsky J, et al. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor α monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis 2017;76:1020–30.
23. Weinblatt M, McInnes I, Kremer J, Miranda P, Vencovsky J, Godwin D, et al. EARTH EXPLORER 2, a phase IIb exploratory study evaluating efficacy and safety of mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor-α monoclonal antibody, and the tumor necrosis factor antagonist golimumab in rheumatoid arthritis. Ann Rheum Dis 2016;75:717–8.
24. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81.
25. Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
26. Van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845–50.
27. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377–81.
28. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
29. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796–806.
30. Van der Heijde DM, van Riel PL, Gribnau FW, Nuver-Zwart IH, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036–8.
31. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.
32. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
33. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005;32:811–9.
34. Achuthan A, Cook AD, Lee MC, Saleh R, Khiew HW, Chang MW, et al. Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation. J Clin Invest 2016;126:3453–66.
35. Jaguin M, Houlbert N, Fardel O, Lecureur V. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. Cell Immunol 2013;281:51–61.
36. Guo X, Wang S, Bay-Jensen AC, Karsdal MA, Godwood A, Albulescu M, et al. Sustained suppression of peripheral biomarkers by mavrilimumab but not golimumab in anti-tumor necrosis factor-inadequate responders: an exploratory analysis in the phase IIb Earth Explorer 2 Clinical Trial [abstract]. Arthritis Rheumatol 2016;68 Suppl 10. URL: http://acrabstracts.org/abstract/sustained-suppression-of-peripheral-biomarkers-by-mavrilimumab-but-not-golimumab-in-anti-tumor-necrosis-factor-inadequate-responders-an-exploratory-analysis-in-the-phase-iib-earth-explorer-2-clinical/.
37. Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc 2007;4:443–8.
38. Tsuchiya Y, Takayanagi N, Sugiura H, Miyahara Y, Tokunaga D, Kawabata Y, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 2011;37:1411–7.
39. Kelly C, Iqbal K, Iman-Gutierrez L, Evans P, Manchegowda K. Lung involvement in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol 2016;30:870–88.
40. Shaw M, Collins BF, Ho LA, Raghu G. Rheumatoid arthritis-associated lung disease. Eur Respir Rev 2015;24:1–16.
41. Cottin V, Tebib J, Massonnet B, Souquet PJ, Bernard JP. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996;109:933–8.
42. Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) 2002;41:262–7.
43. Antoniu SA. GM-CSF pathway correction in pulmonary alveolar proteinosis. Expert Opin Biol Ther 2010;10:1357–65.
44. Khan A, Agarwal R. Pulmonary alveolar proteinosis. Respir Care 2011;56:1016–28.
45. Buch MH, Silva-Fernandez L, Carmona L, Aletaha D, Christensen R, Combe B, et al. Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. Ann Rheum Dis 2015;74:963–9.